# A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)

> **NCT00491738** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** sunitinib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00491738
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2008-01
- **Final completion:** —
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly tolerated.
- **Last updated:** 2009-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00491738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00491738, "A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT00491738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*